Equities analysts predict that Bellus Health Inc. (NYSE:BLU) will report ($0.12) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Bellus Health’s earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.06). Bellus Health posted earnings of ($0.07) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 71.4%. The firm is expected to report its next earnings report on Thursday, February 20th.
According to Zacks, analysts expect that Bellus Health will report full-year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.38) to ($0.19). For the next year, analysts forecast that the company will post earnings of ($0.52) per share, with EPS estimates ranging from ($0.84) to ($0.18). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Bellus Health.
Bellus Health (NYSE:BLU) last posted its earnings results on Thursday, November 14th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.
BLU traded up $0.30 during midday trading on Friday, reaching $8.30. The company had a trading volume of 17,508 shares, compared to its average volume of 459,180. The company’s 50-day moving average price is $7.18. Bellus Health has a 1 year low of $2.63 and a 1 year high of $9.36.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Orbimed Advisors LLC purchased a new stake in Bellus Health in the third quarter worth about $45,129,000. Millennium Management LLC purchased a new stake in Bellus Health in the third quarter worth about $424,000. Finally, Point72 Asset Management L.P. purchased a new stake in Bellus Health in the third quarter worth about $257,000.
Bellus Health Company Profile
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
See Also: Support Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellus Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellus Health and related companies with MarketBeat.com's FREE daily email newsletter.